- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety ...
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma ...
Low-dose dexamethasone with pomalidomide improved overall survival to 12.7 months, compared to 5.7 months with high-dose dexamethasone. elgene International Sàrl, a wholly-owned subsidiary of Celgene ...
Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu MM-013, a ...
Show More From the Divisions of Hematology and Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, MN; Mayo Clinic Arizona, Scottsdale, AZ; and Mayo Clinic Florida, ...
The survival of patients with multiple myeloma has improved tremendously over the years. However, patients with disease that has relapsed and is refractory to thalidomide, lenalidomide and bortezomib ...
Please provide your email address to receive an email when new articles are posted on . Until the last decade, efforts to develop a therapy that successfully targeted the KRAS mutation had been futile ...
- Preliminary results confirm earlier findings that inobrodib in combination with pomalidomide + dexamethasone (InoPd) for multiple myeloma has promising clinical activity and a tolerable safety ...
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback